--- title: "[Editorial] Improve the Drug Pricing Mechanism to Make Medications More Affordable for the Public" type: "News" locale: "en" url: "https://longbridge.com/en/news/282815167.md" description: "The General Office of the State Council recently issued \"Several Opinions on Improving the Price Formation Mechanism for Pharmaceuticals,\" reconstructing the price formation mechanism for drugs, proposing reform measures, and building a new pricing system aimed at making medications more accessible and reasonably priced for the public. This move has sparked a positive market reaction, with most stocks in the A-share innovative drug sector rising. The new policy will encourage high-level innovative drug research and development, promote price transparency for pharmaceuticals, prevent unreasonable bidding behaviors, and ensure that drug prices operate within a reasonable range" datetime: "2026-04-15T09:06:28.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/282815167.md) - [en](https://longbridge.com/en/news/282815167.md) - [zh-HK](https://longbridge.com/zh-HK/news/282815167.md) --- # [Editorial] Improve the Drug Pricing Mechanism to Make Medications More Affordable for the Public Recently, the General Office of the State Council issued the "Several Opinions on Improving the Price Formation Mechanism of Pharmaceuticals" (hereinafter referred to as "Opinions"), reconstructing the pharmaceutical price formation mechanism at the institutional level and proposing a series of reform measures from the perspectives of the entire cycle, all channels, and all fields. On April 15, the State Council Information Office held a regular press conference to further interpret the "Opinions." The "Opinions" clearly propose to establish a new pricing system characterized by "market dominance, medical insurance guidance, diversified support, and dynamic adjustment," regulating the pricing, supply, and payment of pharmaceuticals in key areas, making medications more accessible to the public and ensuring more reasonable price levels. This reflects the country's determination to regulate pharmaceutical price order, safeguard people's livelihoods, and promote high-quality industrial development. As a top-level design document in the field of pharmaceutical pricing, the issuance of the "Opinions" has attracted widespread attention and sparked enthusiastic responses in the market. On April 15, most stocks in the A-share innovative drug sector rose, with several concept stocks hitting the daily limit. In recent years, some drug prices have been excessively high, with excessive markups in the circulation links, an inadequate pricing mechanism for innovative drugs, and significant price differences between regions. These issues have not only increased the medical burden on the public to some extent but have also restricted the healthy development of China's pharmaceutical industry. The "Opinions" improve the drug pricing mechanism, directly addressing public demands, and will further guide drug prices to maintain reasonable levels. In particular, the classification of pricing policies for drugs throughout their lifecycle can leave room for high-level innovative drugs, encouraging companies to continue their research and innovation and actively support high-level innovative drugs with significant clinical value. On the other hand, the "Opinions" also encourage all parties to participate in drug price formation, making drug price information from different channels more open, transparent, and comparable, allowing the public to "compare prices" and make informed purchases. Additionally, measures such as implementing drug price risk warnings, preventing irrational bidding impacts on supply during centralized procurement, and severely punishing illegal behaviors such as "forcing price increases by creating shortages" in the pharmaceutical and raw material sectors will guide drug prices to operate within a reasonable range. At the press conference on the 15th, Wang Xiaoning, Director of the Pharmaceutical Price and Bidding Procurement Department of the National Medical Insurance Administration, pointed out that currently, under competitive pressure and governance rules, prices from different channels are gradually converging and becoming more reasonable. The price comparison mini-programs developed by local designated pharmacies achieve full coverage monitoring of physical pharmacy price levels, making it convenient for the public to find out which pharmacy offers better prices and guiding them to "vote with their feet." Drug prices are a "barometer" of people's livelihood security, a "guiding stick" for industrial development, and a key support for advancing the construction of a healthy China. The "Opinions" adhere to the combination of an effective market and a proactive government, supporting what should be supported, ensuring what should be guaranteed, and governing what should be governed, undoubtedly possessing strong practical relevance. The research, production, and circulation chain of pharmaceuticals is relatively long, and improving the pharmaceutical price formation mechanism is also a complex interactive process that cannot be achieved overnight. However, as long as the market-based foundation for price formation is continuously solidified, a fair competitive market environment is created, and a dynamic adjustment mechanism for drug prices is established to ensure that drug prices match value and demand, while strengthening cross-departmental joint supervision, the market order can be further standardized Make medical treatment and medication more affordable for the public ### Related Stocks - [159748.CN](https://longbridge.com/en/quote/159748.CN.md) - [159992.CN](https://longbridge.com/en/quote/159992.CN.md) ## Related News & Research - [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md) - [CSPC’s ADC SYS6010 Wins New Breakthrough Status in China Esophageal Cancer](https://longbridge.com/en/news/285925629.md) - [Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies | CATX Stock News](https://longbridge.com/en/news/286755419.md) - [08:10 ETSHARx Calls for Accountability as Policymakers Target PBM Practices Nationwide](https://longbridge.com/en/news/286768960.md) - [Cosette Pharmaceuticals Appoints David Bell as Chief Commercial Officer (Brands)](https://longbridge.com/en/news/286911191.md)